Table 1

Schedule of assessments. Day 1 is the first day of microbiologically efficacious antibiotic therapy

Study visit/observation point	1	2	3	4	5	6	7
	Screening	Randomisation	Follow-up
Timeline (study day)	0–5	5	8	12	30	60	90
Window period (days)	±1	±1	±2	±2	±7	±14	±21
Informed consent	X				(X)	(X)	(X)
Entry criteria	X
CRP measurement* (2 mL blood)			X	X
AEs reviewed			X	X
SAEs reviewed			X	X	X	X	X
Other outcomes data collected					X	X	X

*The CRP will not be requested in patients whose antibiotic therapy has already been discontinued.
AE, adverse events; CRP, C reactive protein; SAE, serious adverse events.